Item 8.01. Other Events
On January 14, 2021, DBV Technologies S.A. (the "Company") issued a press
release announcing the Company's receipt from the U.S. Food and Drug
Administration ("FDA") of written responses to questions provided in the Type A
meeting request the Company submitted in October 2020. The Type A meeting
request was submitted following the Company's receipt of a Complete Response
Letter from the FDA in connection with the Company's Biologics License
Application for Viaskin™ Peanut (DBV712), an investigational, non-invasive,
once-daily epicutaneous patch to treat peanut allergy in children ages 4 to 11
years. A copy of the Company's press release is attached hereto as Exhibit 99.1
and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Description
99.1 Press Release, dated January 14, 2021.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses